Skip to main content
ROQUEFORT THERAPEUTICS PLC logo

ROQUEFORT THERAPEUTICS PLC — Investor Relations & Filings

Ticker · ROQ ISIN · GB00BMDQ2T15 LEI · 254900P4SISIWOR9RH34 IL Professional, scientific and technical activities
Open in API
Filings indexed 182 across all filing types
Latest filing 2026-05-29 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL ROQ

About ROQUEFORT THERAPEUTICS PLC

https://www.roquefortplc.com/

Roquefort Therapeutics PLC is a biotechnology company focused on developing next-generation, first-in-class medicines for hard-to-treat cancers. The company operates within the high-growth immuno-oncology market. Its portfolio consists of five novel, patent-protected, pre-clinical anti-cancer programs. These programs are designed to target cancers that have become resistant to existing therapies. Roquefort Therapeutics utilizes a distributed R&D model, combining its in-house expertise and laboratory facilities with a network of partnerships with leading academic cancer research centers to advance its development strategy.

Recent filings

Filing Released Lang Actions
Issue of Equity
Share Issue/Capital Change Classification · 90% confidence The document is an RNS announcement from Coiled Therapeutics plc regarding the issue of 934,783 new ordinary shares, conditional on admission to trading, and details of the company’s post-admission share capital. It clearly describes a new share issue and a capital structure change. This fits the “Share Issue/Capital Change” category.
2026-05-29 English
Notice of Annual General Meeting
Report Publication Announcement Classification · 89% confidence The document is an RNS announcement that the Notice of Annual General Meeting and Forms of Proxy have been posted and are available via a link. It is short, contains no substantive AGM materials, and simply announces the publication of the notice. Under the “menu vs meal” rule, this is a report publication announcement rather than the AGM materials themselves.
2026-05-27 English
Commencement of Trading on US OTCQB Venture Market
Regulatory Filings Classification · 79% confidence The document is an RNS (Regulatory News Service) announcement from the London Stock Exchange announcing commencement of trading on the US OTCQB Venture Market. It is a corporate announcement rather than a financial report, management commentary, or detailed regulatory filing. It does not propose or provide financial statements; it simply announces an event and links to further information. The appropriate category is the general Regulatory Filings (RNS) fallback.
2026-05-19 English
Attendance at Endless Frontier Labs 2026
Regulatory Filings Classification · 95% confidence The document is a press release announcing Coiled Therapeutics' participation and presentation at the Endless Frontier Labs 2026 event. It highlights the company's clinical trial updates and the significance of the event but does not contain any financial statements, detailed financial performance data, or regulatory filings. There is no indication that this is an annual report, earnings release, or any other formal financial or regulatory document. The content is primarily an announcement of a corporate event and business development activity. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other specific categories.
2026-05-07 English
Appointment of Non-Executive Director
Board/Management Information Classification · 95% confidence The document is an announcement dated 7 May 2026 from Coiled Therapeutics plc regarding the appointment of a Non-Executive Director, Dr. Andrew Dean. It details his background, qualifications, and shareholdings. There is no financial data, no mention of a report or financial results, and no regulatory filings or certifications. The content focuses solely on a change in the company's board of directors. This matches the definition of Board/Management Information (MANG). The document length is 7005 characters, sufficient for a detailed announcement but not a full report. Therefore, the correct classification is MANG with high confidence.
2026-05-07 English
Annual Report & Financial Statements
Annual Report Classification · 95% confidence The document is titled 'Annual Report & Financial Statements' and covers the audited results for the year ended 31 December 2025, which is a full fiscal year. It includes detailed information about strategic changes, financial transactions, board changes, clinical program updates, and future outlook. The text contains comprehensive financial and operational data typical of an annual report. It is not a brief announcement or a certification letter, nor is it a transcript, presentation, or interim report. The document length is substantial (15,000 characters), indicating it is the full report rather than a publication announcement. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2026-05-06 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.